These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25338975)

  • 1. A prospective population pharmacokinetic analysis of sapropterin dihydrochloride in infants and young children with phenylketonuria.
    Qi Y; Mould DR; Zhou H; Merilainen M; Musson DG
    Clin Pharmacokinet; 2015 Feb; 54(2):195-207. PubMed ID: 25338975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of sapropterin in patients with phenylketonuria.
    Feillet F; Clarke L; Meli C; Lipson M; Morris AA; Harmatz P; Mould DR; Green B; Dorenbaum A; Giovannini M; Foehr E;
    Clin Pharmacokinet; 2008; 47(12):817-25. PubMed ID: 19026037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients <4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial.
    Muntau AC; Burlina A; Eyskens F; Freisinger P; De Laet C; Leuzzi V; Rutsch F; Sivri HS; Vijay S; Bal MO; Gramer G; Pazdírková R; Cleary M; Lotz-Havla AS; Munafo A; Mould DR; Moreau-Stucker F; Rogoff D
    Orphanet J Rare Dis; 2017 Mar; 12(1):47. PubMed ID: 28274234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia.
    Sanford M; Keating GM
    Drugs; 2009; 69(4):461-76. PubMed ID: 19323589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International best practice for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuria.
    Muntau AC; Adams DJ; Bélanger-Quintana A; Bushueva TV; Cerone R; Chien YH; Chiesa A; Coşkun T; de Las Heras J; Feillet F; Katz R; Lagler F; Piazzon F; Rohr F; van Spronsen FJ; Vargas P; Wilcox G; Bhattacharya K
    Mol Genet Metab; 2019 May; 127(1):1-11. PubMed ID: 31103398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sapropterin dihydrochloride for the treatment of hyperphenylalaninemias.
    Blau N
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1207-18. PubMed ID: 23705856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction of sapropterin dihydrochloride as standard of care in patients with phenylketonuria.
    Vernon HJ; Koerner CB; Johnson MR; Bergner A; Hamosh A
    Mol Genet Metab; 2010 Jul; 100(3):229-33. PubMed ID: 20418136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study.
    Burton BK; Nowacka M; Hennermann JB; Lipson M; Grange DK; Chakrapani A; Trefz F; Dorenbaum A; Imperiale M; Kim SS; Fernhoff PM
    Mol Genet Metab; 2011 Aug; 103(4):315-22. PubMed ID: 21646032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose sapropterin dihydrochloride therapy improves monoamine neurotransmitter turnover in murine phenylketonuria (PKU).
    Winn SR; Scherer T; Thöny B; Harding CO
    Mol Genet Metab; 2016 Jan; 117(1):5-11. PubMed ID: 26653793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study.
    Keil S; Anjema K; van Spronsen FJ; Lambruschini N; Burlina A; Bélanger-Quintana A; Couce ML; Feillet F; Cerone R; Lotz-Havla AS; Muntau AC; Bosch AM; Meli CA; Billette de Villemeur T; Kern I; Riva E; Giovannini M; Damaj L; Leuzzi V; Blau N
    Pediatrics; 2013 Jun; 131(6):e1881-8. PubMed ID: 23690520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study.
    Bratkovic D; Margvelashvili L; Tchan MC; Nisbet J; Smith N
    Metabolism; 2022 Mar; 128():155116. PubMed ID: 34973284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria.
    Lee P; Treacy EP; Crombez E; Wasserstein M; Waber L; Wolff J; Wendel U; Dorenbaum A; Bebchuk J; Christ-Schmidt H; Seashore M; Giovannini M; Burton BK; Morris AA;
    Am J Med Genet A; 2008 Nov; 146A(22):2851-9. PubMed ID: 18932221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study.
    Burton BK; Grange DK; Milanowski A; Vockley G; Feillet F; Crombez EA; Abadie V; Harding CO; Cederbaum S; Dobbelaere D; Smith A; Dorenbaum A
    J Inherit Metab Dis; 2007 Oct; 30(5):700-7. PubMed ID: 17846916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of sapropterin on urinary monoamine metabolites in phenylketonuria.
    Douglas TD; Jinnah HA; Bernhard D; Singh RH
    Mol Genet Metab; 2013 Jul; 109(3):243-50. PubMed ID: 23712020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved metabolic control in tetrahydrobiopterin (BH4), responsive phenylketonuria with sapropterin administered in two divided doses vs. a single daily dose.
    Kör D; Yılmaz BŞ; Bulut FD; Ceylaner S; Mungan NÖ
    J Pediatr Endocrinol Metab; 2017 Jul; 30(7):713-718. PubMed ID: 28593914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unresponsiveness to tetrahydrobiopterin of phenylalanine hydroxylase deficiency.
    Ponzone A; Porta F; Mussa A; Alluto A; Ferraris S; Spada M
    Metabolism; 2010 May; 59(5):645-52. PubMed ID: 19913839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial.
    Muntau AC; Burlina A; Eyskens F; Freisinger P; Leuzzi V; Sivri HS; Gramer G; Pazdírková R; Cleary M; Lotz-Havla AS; Lane P; Alvarez I; Rutsch F
    Orphanet J Rare Dis; 2021 Aug; 16(1):341. PubMed ID: 34344399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sapropterin dihydrochloride in patients with phenylketonuria: A meta-analysis of randomized controlled trials.
    Qu J; Yang T; Wang E; Li M; Chen C; Ma L; Zhou Y; Cui Y
    Br J Clin Pharmacol; 2019 May; 85(5):893-899. PubMed ID: 30720885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients.
    Utz JR; Lorentz CP; Markowitz D; Rudser KD; Diethelm-Okita B; Erickson D; Whitley CB
    Mol Genet Metab; 2012 Feb; 105(2):193-7. PubMed ID: 22112818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sapropterin dihydrochloride: a new drug and a new concept in the management of phenylketonuria.
    Trefz FK; Belanger-Quintana A
    Drugs Today (Barc); 2010 Aug; 46(8):589-600. PubMed ID: 20830319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.